pufa 21:5

PUFA 21:5, formally known as heneicosapentaenoic acid (HPA), is a long‑chain polyunsaturated fatty acid (PUFA) in the omega‑3 family characterized by a chain of 21 carbon atoms with five double bonds. This structural configuration places it as a relatively rare polyunsaturated fatty acid compared with more abundant omega‑3 fats such as eicosapentaenoic acid (EPA, C20:5) and docosahexaenoic acid (DHA, C22:6). In biochemical nomenclature, the designation “21:5n‑3” indicates the carbon chain length (21) and number of double bonds (5) with the first double bond three carbons from the methyl end of the molecule, a hallmark of omega‑3 fatty acids. PUFA 21:5 is found in trace amounts in certain marine organisms and algae and may be incorporated into phospholipids and triacylglycerols in vivo, similar to EPA and DHA. Its presence in food sources tends to be at much lower concentrations than EPA or DHA. The name “heneicosapentaenoic acid” reflects an extension of EPA with an additional carbon atom on the carboxyl end, which shifts the positions of double bonds relative to EPA but retains similar biochemical roles in membrane fluidity and signaling lipid pathways. Biochemically, PUFAs like 21:5 contribute to membrane fluidity and serve as precursors or modulators of signaling molecules, often through competitive pathways with omega‑6 PUFAs that lead to eicosanoid production. While most research on omega‑3 fatty acids centers on EPA and DHA, the existence of 21:5 highlights the diversity of long‑chain PUFAs in nature and their nuanced roles in lipid biology. Because PUFA 21:5 is not an essential fatty acid in the strict sense (its specific health requirements have not been defined), it is typically consumed as part of the broader category of omega‑3 fatty acids. National nutrition guidelines recommend total omega‑3 intake rather than specifying intake for individual rare PUFAs. The body may incorporate traces of 21:5 into cellular lipids, but its functional significance in human health beyond that of the broader omega‑3 class remains under investigation.

PUFA 21:5 belongs to the omega‑3 class of polyunsaturated fatty acids, a group of bioactive lipids known to play roles in membrane structure, cell signaling, and inflammation modulation. Although specific studies isolating PUFA 21:5’s effects in humans are sparse, the broader family of omega‑3 fatty acids has been extensively researched. Omega‑3 PUFAs such as EPA and DHA are incorporated into phospholipid membranes throughout the body, influencing membrane fluidity, receptor function, and the activity of membrane‑bound enzymes. This impacts cardiovascular, immune, and neurological systems. The incorporation of PUFAs into cellular membranes affects ion channel behavior and receptor binding, which in turn can influence neuronal transmission and heart rhythm stability. One of the key mechanistic roles of omega‑3 PUFAs is their involvement in eicosanoid pathways. EPA competes with arachidonic acid (an omega‑6 fatty acid) for conversion by cyclooxygenase and lipoxygenase enzymes, leading to the production of eicosanoids that tend to be less pro‑inflammatory compared with those derived from omega‑6 precursors. Although direct data on PUFA 21:5 are limited, compounds with similar structures such as EPA have been shown in clinical studies to reduce triglycerides and potentially lower cardiovascular risk markers when consumed at sufficient amounts. A 2020 analysis of multiple clinical trials involving omega‑3 supplementation found reductions in triglycerides and some cardiovascular outcomes, especially with EPA and DHA. The overarching health benefit narrative for omega‑3 PUFAs includes support for cardiovascular health, cognitive development and function, anti‑inflammatory effects, and potential contributions to eye health. Many of these effects derive from EPA and DHA’s interactions with gene expression and inflammatory signaling rather than from rare PUFAs. Because PUFA 21:5 may incorporate into the same metabolic and structural pathways, it could theoretically influence similar mechanisms, but specific evidence is lacking. Current understanding emphasizes that adequate total omega‑3 intake supports heart and brain health, but individual contributions of trace components like 21:5 remain under‑researched. More targeted research would be required to elucidate the specific health effects of PUFA 21:5 compared with well‑characterized long‑chain omega‑3s. Until then, its functional significance is inferred through its classification within the broader omega‑3 PUFA family and similarities in chemical structure to better‑studied fatty acids.

There are no specific dietary reference intakes (DRIs) established for PUFA 21:5 alone. National nutrition guidelines, such as those provided by the Institute of Medicine and summarized by the NIH Office of Dietary Supplements, establish Adequate Intake (AI) values for total omega‑3 fatty acids, primarily alpha‑linolenic acid (ALA), because specific long‑chain PUFAs like EPA, DHA, and rarer variants such as 21:5 have insufficient evidence to warrant their own recommendations. For total omega‑3s, the AI for adult males aged 19–50 years is approximately 1.6 grams per day of ALA, and for adult females of the same age it is 1.1 grams per day. These guidelines recognize that ALA is the only essential omega‑3 fatty acid, since the body cannot synthesize it. Long‑chain omega‑3 PUFAs such as EPA and DHA are considered non‑essential in the strict sense because they can be synthesized from ALA, albeit inefficiently. However, because conversion of ALA to EPA (and ultimately to DHA) is limited in humans, dietary intake of EPA and DHA is recommended for cardiovascular and developmental benefits. There are no analogous recommendations for PUFA 21:5. As a result, dietary guidance focuses on consuming sufficient total omega‑3 fatty acids, particularly EPA and DHA, rather than targeting specific minor PUFAs. Factors that affect individual omega‑3 requirements include age, sex, pregnancy status, metabolic health, and overall diet composition. Individuals with higher inflammatory load or cardiovascular risk may benefit from greater omega‑3 intakes, particularly from EPA and DHA sources. The lack of specific guideline values for PUFA 21:5 does not indicate it is unimportant; rather it reflects insufficient evidence to define its own intake recommendations. It is consumed naturally as part of foods rich in omega‑3 fatty acids, and meeting total omega‑3 intake recommendations ensures inclusion of trace amounts of 21:5 for most diets.

Because there are no established deficiency biomarkers or clinical definitions specific to PUFA 21:5, deficiency symptoms are described in the context of overall omega‑3 fatty acid inadequacy rather than an isolated lack of 21:5. Symptoms of omega‑3 deficiency in general can include dry or scaly skin, poor wound healing, decreased immunity, mood disturbances, and suboptimal visual or cognitive function. Populations at risk for low omega‑3 status often have low intakes of fatty fish and plant sources of ALA, leading to reduced levels of EPA, DHA, and minor omega‑3 PUFAs in tissues. Biomarkers to assess omega‑3 status often involve measuring levels of EPA and DHA in plasma phospholipids or erythrocyte membranes. Although there is no clinical diagnostic test for PUFA 21:5 specifically, a comprehensive fatty acid panel can reveal overall omega‑3 PUFA profiles. Deficiency of essential fatty acids broadly can disrupt membrane structure and signaling and contribute to inflammatory imbalance. Because PUFA 21:5 is not considered essential on its own, isolated deficiency is not recognized. Instead, low total omega‑3 tissue levels indicate inadequate dietary intake of omega‑3 fats. Dietary patterns lacking in fish, seafood, flaxseed, chia seeds, and other omega‑3 sources are most often associated with poor omega‑3 status. Research prevalence data have focused on EPA and DHA levels rather than minor PUFAs; for example, plasma EPA and DHA levels are often lower in Western populations with low fish intake compared with populations with high seafood consumption. Without specific clinical criteria, the concept of PUFA 21:5 deficiency remains theoretical and is subsumed under broader omega‑3 deficiency paradigms.

Because PUFA 21:5 occurs in very low concentrations in most foods, the richest sources tend to be marine oils and traditional foods where rare long‑chain PUFAs accumulate. According to nutrient ranking tools and specialized food composition analyses, foods with measurable amounts of heneicosapentaenoic acid include oils from marine mammals and certain fish. Marine mammal oils, such as bearded seal oil and spotted seal oil used historically in Indigenous diets, rank among the highest natural sources of 21:5. Whale (beluga) oil also contains higher levels. Among more commonly consumed fish, species such as sockeye salmon and other native salmon varieties (e.g., coho salmon) contain small but detectable amounts of PUFA 21:5. Other fish like smelt or whitefish have trace levels. Because 21:5 is a component of the broader omega‑3 profile in marine lipids, foods high in omega‑3 fatty acids typically deliver the greatest absolute amounts of long‑chain PUFAs. Oily fish such as salmon, mackerel, sardines, and herring are rich in EPA and DHA and also contain minor PUFAs including 21:5. Plant sources rich in ALA (flaxseed, chia, walnuts) do not typically contain appreciable amounts of 21:5 because plant oils contain shorter‑chain omega‑3s. Incorporation of microalgae oils into diets provides another avenue for consuming diverse PUFA profiles; marine microalgae synthesize many long‑chain omega‑3s and may include trace 21:5. Overall, while PUFA 21:5 occurs at much lower quantitative levels than EPA and DHA, choosing diets rich in oily fish and marine‑derived oils ensures inclusion of this and other long‑chain PUFAs as part of total omega‑3 intake.

Like other dietary fats, PUFA 21:5 is absorbed through the small intestine following digestion by pancreatic lipases and incorporation into micelles with bile salts. Once in enterocytes, fatty acids are re‑esterified into triglycerides and packaged into chylomicrons for transport through lymphatic circulation. The efficiency of absorption for long‑chain PUFAs is high and similar to other omega‑3 fatty acids. Factors that enhance PUFA absorption include concurrent intake of dietary fat and efficient bile salt production, which improves micelle formation. Conversely, conditions impairing fat digestion (e.g., pancreatic insufficiency, cholestatic liver disease) can reduce PUFA absorption and lead to steatorrhea. Bioavailability differences among PUFAs often relate to chain length and degree of unsaturation. Highly unsaturated Long‑chain PUFAs like EPA and DHA are efficiently incorporated into cellular membranes and lipoproteins, whereas very long‑chain or rare PUFAs may have distinct tissue distribution patterns. PUFA 21:5, sharing structural similarity with EPA, likely follows similar absorption and incorporation pathways. Because it circulates within chylomicrons and lipoproteins, it may be delivered to liver and peripheral tissues where it can be integrated into phospholipids or oxidized for energy. Dietary factors such as phytosterols may modestly inhibit PUFA absorption by competing for incorporation into micelles. Additionally, co‑consumption of antioxidants like vitamin E may protect highly unsaturated PUFAs from oxidative degradation during absorption and transport.

There are no supplements marketed specifically for PUFA 21:5, and no clinical guidelines recommend isolating this fatty acid for supplementation. Instead, nutritional advice centers on consuming total omega‑3 fatty acids—especially EPA and DHA—through diet or supplements. Common omega‑3 supplements include fish oil, krill oil, and algal oil, which provide significant amounts of EPA and DHA. Some microalgae‑derived oils also offer vegetarian sources of long‑chain omega‑3s and may contain trace amounts of other PUFAs. Individuals with low dietary intake of marine foods or those with specific health conditions (e.g., high triglycerides) may benefit from routine omega‑3 supplementation under healthcare guidance. Evidence from systematic reviews suggests that daily intakes of around 1 gram of combined EPA and DHA may reduce certain cardiovascular risk markers and triglyceride levels. Because PUFA 21:5 is a minor component in typical omega‑3 PUFA supplements, its presence is incidental rather than a targeted therapeutic ingredient. Quality considerations for omega‑3 supplements include purity (free of heavy metals), stability (oxidation resistance), and appropriate dosing. Supplements may be advisable for individuals with limited seafood intake, but clinicians do not recommend supplements solely for rare PUFAs like 21:5. Should research evolve to establish specific physiological roles for 21:5, product formulations might adapt; however, current evidence supports total omega‑3 intake as the priority.

There are no established tolerable upper intake levels (ULs) for PUFA 21:5 on its own. Toxicity concerns for omega‑3 fatty acids more broadly relate to very high intakes of supplements, which may increase bleeding risk or interact with medications affecting coagulation. The Food and Nutrition Board has not set a UL for total omega‑3 fatty acids because adverse effects are uncommon at typical dietary intakes. Extremely high supplemental intakes of EPA and DHA (several grams per day) may modestly increase risk of hemorrhagic complications in susceptible individuals. Because PUFA 21:5 is consumed in trace amounts as part of total omega‑3 intake, concerns about direct toxicity are negligible. As with other highly unsaturated lipids, oxidative degradation products from PUFA supplements can produce off‑flavors and potentially pro‑oxidant compounds if products are rancid, underscoring the importance of choosing high‑quality, stabilized supplements.

PUFA 21:5 itself has not been studied for specific drug interactions, but omega‑3 fatty acid intake as a class can interact with several medications. High intake of omega‑3s may have additive effects with anticoagulant and antiplatelet drugs, potentially increasing bleeding risk when used with warfarin, aspirin, clopidogrel, or direct oral anticoagulants. Monitoring by a healthcare provider is recommended for patients on these medications who consume large amounts of omega‑3 supplements. Omega‑3s can also interact with lipid‑lowering drugs such as statins and fibrates, sometimes enhancing triglyceride‑lowering effects. Because PUFA 21:5 is a minor component of the omega‑3 pool, any interaction would reflect overall omega‑3 intake rather than this specific fatty acid. Patients should discuss supplement use with prescribers to avoid unexpected changes in medication efficacy or side effects.

Common Forms: Fish oil capsules, Algal omega‑3 oil, Krill oil

Typical Doses: 1 g/day combined EPA/DHA for cardiovascular support

When to Take: With meals to enhance absorption

Best Form: Triglyceride or phospholipid bound omega‑3 forms

⚠️ Interactions: Anticoagulant medications (e.g., warfarin)